Table 2.
Case reports of CAZ-AVI for multidrug-resistant PA-CNSI.
| Study | Age (y) | Gender | Country | Comorbidity | Pathogen | Regimen | Duration | CSF culture conversion | ADR | Outcome |
|---|---|---|---|---|---|---|---|---|---|---|
| Yasmin et al. (81) | 69 | M | USA | subarachnoid hemorrhage | DTR-PA | CAZ-AVI 2.5 g, ivgtt, q8h + CMS 4.5 MIU, ivgtt, q12h + CMS 125000 IU, ITH q12h | ≥21 d | Yes | None | Cured |
| Zhou et al. (82) | 21 | M | China | head trauma | DTR-PA | CAZ-AVI 1.25 g, ivgtt, q8h + AMK 600 mg, ivgtt, qd | 20 d | Yes | None | Cured |
| Gofman et al. (83) | 32 | M | USA | cerebral hemorrhage | CRPA | CAZ-AVI 2.5 g, ivgtt, q8h + AMK 30 mg, ITH, qd | 42 d | Yes | None | Cured |
| Almangourl et al. (84) | 2 | M | Saudi Arabia | hydrocephalus | DTR-PA | CAZ-AVI 187.5 mg/kg/d, ivgtt, q8h + CMS(D1: 30000 IU, IVT qd; D2-D3: 6000 IU, IVT qd; D4-D14: 125000 IU, IVT, qd) | 21 d | Yes | None | Cured |
| Xipell et al. (85) | 56 | F | Spain | brain abscess | DTR-PA | CAZ-AVI 2.5 g, ivgtt, q8h + CMS 2 MIU, ivgtt, q8h | 30 d | Yes | None | Cured |
| Yuan et al. (30) | 14 | M | China | ventricular tumor | DTR-PA | CAZ-AVI 2.5 g, ivgtt, q8h + CMS 125000 IU, ITH qd | 14 d | Yes | None | Cured |
| Rodríguez-Núñez et al. (86) | 58 | F | Spain | sinusitis | XDR-PA | CAZ-AVI*, ivgtt + CMS* ivgtt | 38 d | Yes | None | NA |
| Gatti et al. (87) | 52 | M | Italy | pineal tumor | DTR-PA | CAZ-AVI 15 g, q8h, CI + FOF 24 g, qd, CI | 24 d | Yes | None | Cured |
DTR-PA, Pseudomonas aeruginosa with difficult-to-treat resistance; CAZ-AVI, ceftazidime-avibactam; ivgtt, intravenous infusion; q8h, every 8 h; q12h, every 12 h; qd, once daily; CMS, colistimethate sodium; ITH, intrathecal; AMK, amikacin; CRKP, carbapenem-resistant Klebsiella pneumoniae; CRPA, carbapenem-resistant Pseudomonas aeruginosa; IVT, intraventricular; XDR-PA, extensively drug-resistant Pseudomonas aeruginosa; *, unspecified dosage; NA, not available; FOF, fosfomycin; CI, continuous infusion.